As of 1:21:31 PM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 3 | 5 | 5 |
| Avg. Estimate | -0.28 | -0.29 | -1.12 | -1.22 |
| Low Estimate | -0.3 | -0.3 | -1.15 | -1.42 |
| High Estimate | -0.24 | -0.27 | -1.08 | -1.08 |
| Year Ago EPS | -0.11 | -0.32 | -1.36 | -1.12 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 6 | 6 |
| Avg. Estimate | 1.51M | 1.38M | 3.6M | 6.98M |
| Low Estimate | 500k | 725k | 2.7M | -- |
| High Estimate | 2.8M | 2.5M | 5M | 20M |
| Year Ago Sales | 7.21M | 566k | 21.05M | 3.6M |
| Sales Growth (year/est) | -79.06% | 144.04% | -82.89% | 93.95% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.25 | -0.24 | -0.28 | -0.29 |
| EPS Actual | -0.11 | -0.32 | -0.28 | -0.25 |
| Difference | 0.14 | -0.08 | 0 | 0.04 |
| Surprise % | 55.82% | -31.15% | 1.35% | 14.32% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.28 | -0.29 | -1.12 | -1.22 |
| 7 Days Ago | -0.28 | -0.29 | -1.12 | -1.22 |
| 30 Days Ago | -0.31 | -0.29 | -1.2 | -1.36 |
| 60 Days Ago | -0.31 | -0.29 | -1.2 | -1.36 |
| 90 Days Ago | -0.31 | -0.29 | -1.2 | -1.36 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 1 | 1 | 1 |
| Up Last 30 Days | 2 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| TCRX | -150.18% | 9.38% | 17.53% | -8.81% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/11/2024 |
| Reiterates | Needham: Buy to Buy | 12/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2024 |
| Reiterates | Needham: Buy to Buy | 11/12/2024 |
| Reiterates | Needham: Buy to Buy | 11/6/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 8/13/2024 |
Related Tickers
BCYC Bicycle Therapeutics plc
15.53
+12.42%
ANAB AnaptysBio, Inc.
16.97
+8.85%
VOR Vor Biopharma Inc.
0.9987
+0.76%
SLRN Acelyrin, Inc.
3.4100
+5.57%
RPTX Repare Therapeutics Inc.
1.7000
-3.94%
VRDN Viridian Therapeutics, Inc.
22.91
+28.32%
LVTX LAVA Therapeutics N.V.
1.0300
-7.21%
NRIX Nurix Therapeutics, Inc.
21.07
+3.95%
ADCT ADC Therapeutics SA
2.0450
+8.20%
OKUR OnKure Therapeutics, Inc.
9.49
-3.75%